Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239838 | 1.00 | PIK3CD (0.34) | PIK3CDGPR119ALOX5APFEN1MAP4K4 | |
| SCHEMBL30704241 | 1.00 | PIK3CD (0.34) | PIK3CDGPR119ALOX5APFEN1MAP4K4 | |
| SCHEMBL31239975 | 1.00 | PIK3CD (0.34) | PIK3CDGPR119ALOX5APFEN1MAP4K4 | |
| SCHEMBL26949337 | 1.00 | PIK3CD (0.34) | PIK3CDGPR119ALOX5APFEN1MAP4K4 | |
| SCHEMBL31239996 | 1.00 | PIK3CD (0.34) | PIK3CDGPR119ALOX5APFEN1MAP4K4 | |
| SCHEMBL31239919 | 0.93 | PIK3CD (0.34) | PIK3CDGPR119ALOX5APFEN1MAP4K4 | |
| SCHEMBL31240025 | 0.90 | PIK3CD (0.34) | PIK3CDGPR119 | |
| SCHEMBL31239791 | 0.90 | ALOX5AP (0.32) | PIK3CDGPR119ALOX5APFEN1 | |
| SCHEMBL31240060 | 0.90 | GPR119 (0.32) | GPR119ALOX5APFEN1 | |
| SCHEMBL31239759 | 0.89 | GPR119 (0.33) | PIK3CDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| WO-2024229447-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | PIK3CD 81/4885GPR119 1514/4885ALOX5AP 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.